<DOC>
	<DOCNO>NCT01497899</DOCNO>
	<brief_summary>This study evaluate efficacy elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide ( Genvoya® ; E/C/F/TAF ) fixed-dose combination ( FDC ) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate ( Stribild® ; E/C/F/TDF ) FDC HIV-1 infect , antiretroviral treatment-naive adult .</brief_summary>
	<brief_title>Safety Efficacy E/C/F/TAF ( Genvoya® ) Versus E/C/F/TDF ( Stribild® ) HIV-1 Infected , Antiretroviral Treatment-Naive Adults</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Elvitegravir , Cobicistat , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Ability understand sign write informed consent form Plasma HIV 1 RNA level ≥ 5,000 copies/mL No prior use approved experimental antiHIV drug length time Screening genotype report must show sensitivity TDF emtricitabine ( FTC ) Normal ECG Adequate renal function : Estimated glomerular filtration rate ≥ 70 mL/min accord Cockcroft Gault formula Hepatic transaminases ≤ 2.5 x upper limit normal range ( ULN ) Total bilirubin ≤ 1.5 mg/dL , normal direct bilirubin Adequate hematologic function CD4+ cell count &gt; 50 cells/µL Serum amylase ≤ 5 x ULN Normal thyroidstimulating hormone ( TSH ) Females childbearing potential must negative serum pregnancy test Females childbearing potential must agree utilize highly effective contraception method screen throughout duration study treatment 30 day follow last dose study drug Female subject utilize hormonal contraceptive one birth control method must use method least three month prior study dose Female subject postmenopausal must documentation cessation menses ≥ 12 month hormonal failure Female subject stop menstruate ≥ 12 month documentation ovarian hormonal failure must serum follicle stimulate hormone ( FSH ) level test screen Male subject must agree utilize highly effective method contraception heterosexual intercourse throughout study period 90 day follow discontinuation investigational medicinal product Age ≥ 18 year Life expectancy ≥ 1 year New AIDSdefining condition diagnose within 30 day prior screen Hepatitis B surface Antigen positive Hepatitis C Antibody positive Proven acute hepatitis 30 day prior study entry Subjects experience decompensated cirrhosis Females breastfeed Positive serum pregnancy test ( female childbearing potential ) Have implant defibrillator pacemaker Receiving ongoing therapy disallow medication , include drug use elvitegravir cobicistat Have treat immunosuppressant therapy chemotherapeutic agent within 3 month study screening , expect receive agent systemic steroid study Current alcohol substance History ongoing malignancy ( include untreated carcinoma insitu ) cutaneous Kaposi 's sarcoma ( KS ) , basal cell carcinoma resect , noninvasive cutaneous squamous carcinoma Active , serious infection ( HIV 1 infection ) require parenteral antibiotic antifungal therapy within 30 day prior Baseline Participation clinical trial without prior approval prohibit participate trial Medications contraindicate use emtricitabine tenofovir disoproxil fumarate Any known allergy excipients E/C/F/TAF E/C/F/TDF FDC tablets Any clinical condition prior therapy would make subject unsuitable study unable comply dosing requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>HIV</keyword>
	<keyword>Treatment-Naive</keyword>
</DOC>